Impact of Single-Pill Antihypertensive Regimens on Major Adverse Cardiovascular Events

Article Impact Level: HIGH
Data Quality: STRONG
Summary of  Hypertension https://doi.org/10.1161/HYP.0000000000000258 
Dr. Jordan B. King  et al.

Points

The American Heart Association identifies single-pill combinations as a primary strategy to improve blood pressure control among the one hundred twenty-two million adults currently diagnosed with hypertension.
Observational studies link the use of these consolidated medications to a fifteen to thirty percent reduction in major adverse cardiovascular events compared to multi-pill regimens.
Clinical guidelines now recommend initiating therapy with a single-pill combination for patients presenting with stage 2 hypertension defined as blood pressure exceeding 140 over 90.
Simplifying treatment regimens helps overcome therapeutic inertia and improves patient adherence by reducing the daily pill burden associated with managing chronic cardiovascular conditions.
Widespread adoption of these combination therapies could help mitigate the annual direct and indirect costs of cardiovascular disease which are estimated at over four hundred billion dollars.

Summary

This scientific statement from the American Heart Association evaluates the clinical efficacy of single-pill combination (SPC) therapy for the management of hypertension, a condition affecting approximately 122 million U.S. adults. With less than 50% of treated patients achieving the recommended blood pressure target of less than 130/80 mm Hg, the 2025 AHA/ACC guidelines advocate for initiating treatment with two agents—ideally as an SPC—for those with stage 2 hypertension (≥140/90 mm Hg). The statement differentiates SPCs, which combine antihypertensive classes like ACE inhibitors or ARBs with calcium channel blockers, from polypills that include statins, emphasizing SPCs as a tool to mitigate therapeutic inertia and reduce pill burden.

Observational data reviewed in the statement indicates that SPC adherence is superior to free-equivalent combination regimens, leading to faster attainment of blood pressure goals. Crucially, studies with follow-up periods of one to five years demonstrated that SPC utilization is associated with a 15% to 30% reduction in the risk of major adverse cardiovascular events, including myocardial infarction, stroke, and heart failure hospitalization. Despite these benefits, current adoption is hindered by perceived limitations in dosing flexibility and insurance formularies that favor separate generic components.

The authors argue that widespread implementation of SPCs could significantly lower the $417.9 billion annual economic burden of cardiovascular disease by improving long-term adherence and outcomes. While approximately 200 unique combinations exist, the statement calls for expanded options and further research into triple and quadruple combinations. Continued investigation is also required to establish safety profiles for high-risk populations, including those with resistant hypertension and chronic kidney disease, to facilitate broader clinical uptake.

Link to the article: https://www.ahajournals.org/doi/10.1161/HYP.0000000000000258

References

King, J. B., An, J., Bellows, B. K., Cohen, J. B., Commodore-Mensah, Y., Ghazi, L., Langford, A. T., Brook, R. D., & on behalf of the American Heart Association Council on Hypertension; Council on Cardiovascular and Stroke Nursing; and Council on Clinical Cardiology. (2025). Single-pill combination therapy for the management of hypertension: A scientific statement from the american heart association. Hypertension, HYP.0000000000000258. https://doi.org/10.1161/HYP.0000000000000258